Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan (SKB264) + Brain Radiotherapy in EGFR+ Advanced NSCLC With Brain Metastasis
NCT07789444Phase 2Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Jul 2027
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) and brain metastasis (BM). Primary endpoint: Intracranial Progression-Free Survival at 12 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT07789444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789444.